Biomarkers in stable coronary artery disease

Cian P. McCarthy, John W. McEvoy, James L. Januzzi

Research output: Contribution to journalReview article

Abstract

Coronary artery disease (CAD) remains a significant cause of morbidity and mortality around the world. Patients with stable CAD can have an unpredictable clinical trajectory; thus, additional tools to prognosticate risk in this cohort are warranted. In recent years, a wide range of biomarkers has been recognized for their diagnostic capabilities in patients with stable CAD, identifying those with obstructive disease who may require more intensive preventive therapies or even consideration of percutaneous coronary intervention in some circumstances. In addition, a multiple-biomarker approach may identify stable CAD patients at highest risk for future major adverse cardiac events. Thus, randomized controlled trials to assess biomarker-guided preventive therapy in this cohort appear warranted.

LanguageEnglish (US)
Pages82-96
Number of pages15
JournalAmerican Heart Journal
Volume196
DOIs
StatePublished - Feb 1 2018

Fingerprint

Coronary Artery Disease
Biomarkers
Percutaneous Coronary Intervention
Randomized Controlled Trials
Morbidity
Mortality
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Biomarkers in stable coronary artery disease. / McCarthy, Cian P.; McEvoy, John W.; Januzzi, James L.

In: American Heart Journal, Vol. 196, 01.02.2018, p. 82-96.

Research output: Contribution to journalReview article

McCarthy CP, McEvoy JW, Januzzi JL. Biomarkers in stable coronary artery disease. American Heart Journal. 2018 Feb 1;196:82-96. Available from, DOI: 10.1016/j.ahj.2017.10.016
McCarthy, Cian P. ; McEvoy, John W. ; Januzzi, James L./ Biomarkers in stable coronary artery disease. In: American Heart Journal. 2018 ; Vol. 196. pp. 82-96
@article{5bab70ec54284b0dbe161e0828b49279,
title = "Biomarkers in stable coronary artery disease",
abstract = "Coronary artery disease (CAD) remains a significant cause of morbidity and mortality around the world. Patients with stable CAD can have an unpredictable clinical trajectory; thus, additional tools to prognosticate risk in this cohort are warranted. In recent years, a wide range of biomarkers has been recognized for their diagnostic capabilities in patients with stable CAD, identifying those with obstructive disease who may require more intensive preventive therapies or even consideration of percutaneous coronary intervention in some circumstances. In addition, a multiple-biomarker approach may identify stable CAD patients at highest risk for future major adverse cardiac events. Thus, randomized controlled trials to assess biomarker-guided preventive therapy in this cohort appear warranted.",
author = "McCarthy, {Cian P.} and McEvoy, {John W.} and Januzzi, {James L.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.ahj.2017.10.016",
language = "English (US)",
volume = "196",
pages = "82--96",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Biomarkers in stable coronary artery disease

AU - McCarthy,Cian P.

AU - McEvoy,John W.

AU - Januzzi,James L.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Coronary artery disease (CAD) remains a significant cause of morbidity and mortality around the world. Patients with stable CAD can have an unpredictable clinical trajectory; thus, additional tools to prognosticate risk in this cohort are warranted. In recent years, a wide range of biomarkers has been recognized for their diagnostic capabilities in patients with stable CAD, identifying those with obstructive disease who may require more intensive preventive therapies or even consideration of percutaneous coronary intervention in some circumstances. In addition, a multiple-biomarker approach may identify stable CAD patients at highest risk for future major adverse cardiac events. Thus, randomized controlled trials to assess biomarker-guided preventive therapy in this cohort appear warranted.

AB - Coronary artery disease (CAD) remains a significant cause of morbidity and mortality around the world. Patients with stable CAD can have an unpredictable clinical trajectory; thus, additional tools to prognosticate risk in this cohort are warranted. In recent years, a wide range of biomarkers has been recognized for their diagnostic capabilities in patients with stable CAD, identifying those with obstructive disease who may require more intensive preventive therapies or even consideration of percutaneous coronary intervention in some circumstances. In addition, a multiple-biomarker approach may identify stable CAD patients at highest risk for future major adverse cardiac events. Thus, randomized controlled trials to assess biomarker-guided preventive therapy in this cohort appear warranted.

UR - http://www.scopus.com/inward/record.url?scp=85035751004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035751004&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2017.10.016

DO - 10.1016/j.ahj.2017.10.016

M3 - Review article

VL - 196

SP - 82

EP - 96

JO - American Heart Journal

T2 - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -